MedTrace Logo

Using MASL to Combat Oral Cancer

NCT04188665 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-20

Study results available
· View outcomes & findings →

Summary

This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

MASL

Patients treated with MASL lozenge

OTHER

Placebo

Patients treated with placebo lozenge

Sponsors & Collaborators

  • Rutgers University

    collaborator OTHER

  • Rowan University

    lead OTHER

Principal Investigators

  • Gary S Goldberg · Rowan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2024-12-31
Completion
2025-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04188665 on ClinicalTrials.gov